Researchers discovered that renal medullary carcinoma (RMC) cells use an adaptive mechanism called “myeloid mimicry” to hide from the immune system and promote disease hyper progression after immunotherapy, highlighting specific targets that overcome treatment resistance in preclinical models.
The study was led by Pavlos Msaouel, M.D., Ph.D., and Giannicola Genovese, M.D., Ph.D., both associate professors of Genitourinary Medical Oncology; Jianjun Gao, M.D., Ph.D., professor of Genitourinary Medical Oncology; and Linghua Wang, M.D., Ph.D., associate professor of Genomic Medicine, associate member of the James P. Allison Institute™ and focus area co-lead for the Institute for Data Science in Oncology.